General Announcement::Press Release - Breakthrough Sublingual Wafers Raise NAD+ Levels, Enhance Well-Being in Human Trial

Issuer & Securities

Issuer/ Manager
IX BIOPHARMA LTD.
Securities
IX BIOPHARMA LTD. - SG1BD9000009 - 42C
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
09-Jul-2024 18:57:54
Status
New
Announcement Sub Title
Press Release - Breakthrough Sublingual Wafers Raise NAD+ Levels, Enhance Well-Being in Human Trial
Announcement Reference
SG240709OTHRUCT6
Submitted By (Co./ Ind. Name)
Gwendolin Lee Soo Fern
Designation
Company Secretary
Description (Please provide a detailed description of the event in the box below)
Please refer to the attached.

This announcement has been reviewed by the Company's sponsor, UOB Kay Hian Private Limited (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Lance Tan, Senior Vice President, at 8 Anthony Road, #01-01, Singapore 229957, telephone (65) 6590 6881.

Attachments

Press Release - SL-NAD Human Trial Results - final.pdf
Total size =163K